FiveFingers Classic On Sale Clinical Research Indi

0411awosfd

ia is fast gearing and rising up to the challenge and catering to the needs of the clinical research industry. It is being organized as "Tomorrow’s Market". Global consultancy McKinsey and Co estimates that by 2010, global pharma majors would spend around USD 1-1.5 billion just for clinical trial in the country.
In 2006, 5.5% of all global pharmaceutical patent applications (WIPO PCT applications) named one inventor or more were located in India, and 8.4% in China. This had increased fourfold from that in 19951.
Cost pressures, the need to tap global talent, and growth opportunities in emerging markets has led Western pharmaceutical companies to shift substantial manufacturing and clinical-trial works to India and China, according to a new study. Big pharmaceutical companies like Merck, Eli Lilly and Johnson and Johnson are now counting these two countries for advanced research and development.
India has several experienced CROs offering services across all clinical trial phases. The CROs have been successfully adhering to quality standards and the output is similar to that of developed markets. The territory has very strong data management capabilities and IT skills. Indian scientists are rapidly innovating and creating their own intellectual property as a result of Research and Development activities.
There are significant cost and patient enrollment advantages. India offers a large 'treatment na?ve' patient population. Patient population is vast and diseases are diverse in nature but similar to the epidemiological profile of mature markets. Due to the lack of penetration of effective medical treatment,[link widoczny dla zalogowanych], patient enrollment is high with minimal attrition. They can be recruited for less than one-third the time taken in the US. The average number of patients per site is five times higher than that in the US. However uneven infrastructure and shortage of clinical research assistants could hamper future growth in the outsourcing of clinical trials.
India tipped for 15% share of clinical sector by 2012
・ Shifting clinical trial operations from Western markets to India can reap substantial benefits for sponsors in saved costs and time,[link widoczny dla zalogowanych], according to KPMG’s just-published report India Pharma Inc. And while the operating environment for Indian clinical research organizations (CROs) is very competitive,iveFingers Classic Smartwool What Does The Apprais, particularly from other emerging markets such as Eastern Europe and China, the country has the potential to "emerge as the foremost destination for outsourcing of this integral R&D function."
・ The Indian market for clinical research outsourcing was valued at around $200m in 2007 - nearly three times its value in 2001-02. It is predicted to reach a value of $1.2b by 2010, with a 15 per cent share of the global clinical trials market in the following year.
That growth trend is expected to continue thanks to the fact that India is among the least expensive of all the other emerging markets, roughly on a par with Russia,[link widoczny dla zalogowanych], and can command the highest patient recruitment rates.
About Author:
Nidesh Khatri is Director - B.D. with Med Devices Lifesciences Pvt. Ltd.; Visit the site for more information about Clinical Research.
Report this article
This article is free for republishing